About wpadmin

This author has not yet filled in any details.
So far wpadmin has created 40 blog entries.

Lipum at Biostock Live – among listed companies

At this event we will present the progress of our unique and EU Horizon 2020 supported approach for treatment of chronic inflammatory diseases. In addition, it will also be an opportunity to learn more about Orexo with a market cap of SEK 2.6 billion. Surprisingly, the brilliant Swedish pop group Torsson will be represented. In [...]


Exclusive partnering with nordic life science startups

Thursday 7th February we will spend with potential investors and partners together with 14 participating companies from Umeå. It's the annual Biotech Umeå Investment Day 2019. We are looking forward to this event since we are at the stage of finding investors for our exciting progress towards a new drug against chronic inflammatory diseases. We [...]


There are plenty of opportunities in crowded immunology markets

  According to Johnson & Johnson there are still tons of opportunity in the immunology market, even though it´s crowded. Jennifer Taubert, executive vice president and worldwide pharma chairman recently said at the J.P. Morgan Healthcare Conference: “We do look at immunology as being very, very attractive, and in certain areas, there’s so much unmet medical [...]


Lipum makes a share issue for faster progress

Being a European Commission Horizon 2020 beneficiary has a distinct positive impact on our development. The 2.2 M€ grant enables us to proceed faster towards a new drug against chronic inflammatory diseases. To further increase the momentum we are now raising additional funding by a share issue. Interested investors get a chance to join the [...]


Lipum – towards production of its lead candidate

A range of CMO partners have been evaluated for cell line development and production of Lipum’s antibody. Next weeks our CEO and CMC Project Manager will travel to both Europe and the US visiting contract manufacturers before selecting this critical collaboration partner. To be continued ...


“Investors are interested” – interview with CEO Einar Pontén

An article from Biostock In the northern of Sweden, Umeå, the privately owned company Lipum wants to draw the game plan for the treatment of chronic inflammatory diseases. The main assets are a new drug candidate and promising preclinical result for a unique target molecule. BioStock has met CEO Einar Pontén and discussed the past year [...]


Biotech Umeå Investment Day 2019

An opportunity for investors on Thursday the 7th of February 2019. An efficient full day of exclusive one-to-one partnering at the Biotech Umeå Investment Day 2019. Book your meeting with Lipum at Grand Hôtel in Stockholm. In addition, you can meet with up to 14 different life science companies that are in early development or [...]


BIO-Europe in Copenhagen, Nov 5-7 2018

Lipum offer a new route for treatment of chronic inflammatory diseases. Meet with our CEO Einar Pontén and our CMC Project Manager Mats Reslow at BIO-Europe 2018 in Copenhagen, Nov 5-7. We will tell you more on our novel target Bile Salt-Stimulated Lipase (BSSL) and our ongoing development of a therapeutic antibody for treatment of these [...]


Lipum receives 2.2 M€ grant from Horizon 2020

Lipum's unique approach for treatment of chronic inflammatory diseases receives 2.2 M€ support from EU Horizon 2020, the EU framework program for research and development, will grant 2.2 million euros to Lipum’s ongoing development of a biological pharmaceutical for treatment of chronic inflammatory diseases. Lipum has identified the novel target molecule Bile Salt-Stimulated Lipase (BSSL). [...]